(2025): Online ahead of print
By pairing low-dose GLP-1 medications with rigorous blood diagnostics and behavioral coaching, Noom aims to intercept metabolic dysfunction before it becomes chronic disease
This raises potential concerns for patients with pancreatic and gastrointestinal neuroendocrine cancer or those with genetic conditions like multiple endocrine neoplasia syndrome (MEN1), which predispose individuals to NENs
Wootten D, Miller LJ, Koole C, et al
aim for a deficit of 400 to 500 calories per day, not the 1,000-plus deficit GLP-1 drugs create on their own
How Comprehensive Programs Change Everything The difference between medication-only approaches and comprehensive medical weight loss programs becomes clear when you examine real-world results